<DOC>
	<DOCNO>NCT01878890</DOCNO>
	<brief_summary>Hypothesis : encouraging result phase II study FAVE treatment hormonal resistant prostate cancer lead u continue clinical development efavirenz . Furthermore , available pre-clinical clinical data lead u conduct Phase 1 study efavirenz . Objective Phase I test dose 600 mg / day patient cancer order determine maximum tolerate dose improve therapeutic effect . This study single center Phase I trial , conduct dose escalation scheme efavirenz continual reassessment method likehood approach ( CRML ) solid tumour ( except pancreatic cancer ) non-Hodgkin lymphoma ( NHL ) . Main objective determine safety profile , particularly maximum tolerate dose efavirenz treatment patient solid tumor ( except pancreatic cancer ) NHL therapeutic failure . Secondary objective : - Evaluate efavirenz pharmacokinetics 2 , 4 12 week ; - Evaluate objective response 12 week ; - Evaluate progression free survival 6 month ; - Assess biological progression-free survival 6 month ( prostate tumour ) . Primary Endpoint Safety evaluate accord toxicity scale NCI-CTCAE v4.0 . Dose limit toxicity collect first 28 day ( + / - 7 day ) first dose Efavirenz define follow : - Any drug-related toxicity grade ≥ 3 accord NCI-CTCAE v4.0 ( except alopecia , nausea vomiting , regardless grade ) , - Any drug-related toxicity , regardless grade , lead treatment delay &gt; 14 day , - Score ≥ 19 HAD treatment . Secondary Criteria - Solid tumor : response progression define RECIST v1.1 [ Eisenhauer EA et al . EJC 2009 ) . - Non-Hodgkin lymphoma : Response progression define accord Cheson criterion [ Cheson BD et al . JCO 1999 ] - Biological progression ( particular case prostate tumor ) : define accord Scher [ Scher HI et al . JCO 2008 ] Statistical Considerations This Phase I dose escalation strategy use method CRML , describe O'Quigley Shen [ O'Quigley et al . Biometrics 1996 ] commonly use Phase I trials oncology . - Maximum number eligible evaluable subject 30 . - Six dose level initially define : 600 mg , 1200 mg , 1800 mg , 2200 mg , 2600 mg , 3000 mg. - The risk dose limit toxicity maximum allow 25 % .</brief_summary>
	<brief_title>Phase I Dose Escalation Trial Efavirenz Patients With Solid Tumours Non-Hodgkin Lymphoma Therapeutic Failure .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria : 1 . Patients solid tumor ( except pancreatic cancer ) nonHodgkin lymphoma 2 . Metastatic disease locally advance inoperable tumor , accessible standard therapy . 3 . Male female ≥ 18 year &lt; 80 year . 4 . Tumor assessable RECIST v1.1 , Scher Cheson 2008 99 . 5 . At least 28 day completion prior treatment ( radiotherapy , systemic chemotherapy major surgery ) . 6 . Patient recover prior toxicity ≤ grade 1 . 7. WHO 01 7 day inclusion . 8 . Neutrophils ≥ 1500/mm3 , Platelets ≥ 100 000/mm3 . 9 . Total bilirubin serum creatinine within normal limit ( ≤ 1.5 ULN ) , creatinine clearance ≥ 40 ml / min . 10 . AST / ALT ≤ 1.5 ULN ( ≤ 5 ULN liver metastasis ) . 11 . Normal thyroid function . 12 . Normal coagulation : TP ≥ 70 % . 13 . Life expectancy upper 3 month . 14 . HAD score &lt; 13 . 15 . Negative pregnancy test woman likely pregnant within 7 day inclusion . 16 . Effective contraception duration treatment ( sexes childbearing reproductive age ) : mechanic contraception method always use combination contraceptive method ( eg , oral hormonal contraceptive ) . Because long halflife efavirenz , recommend use adequate contraceptive measure 12 week stop treatment efavirenz . 17 . Informed consent sign date patient legal representative establishment specific procedure study . 18 . Clinical examination laboratory test make within 7 day enrollment start treatment . 19 . Initial assessment radiological CT / MRI perform within 30 day enrollment . 20 . Patients potentially compliant treatment followup study . 21 . Ability swallow capsule tablet . 22 . Patients insured social security system . Exclusion Criteria : 1 . Patient pancreatic cancer . 2 . Presence active symptomatic cerebral localization ( know ) . 3 . History another cancer except : cancer occur five year consider complete remission situ cervix carcinoma , cutaneous basal cell carcinoma . 4 . Current major depressive state ( screen HAD scale total score ≥ 13 ) . 5 . Patients history depressive disorder , suicide attempt , addiction psychiatric disorder . 6 . Concomitant use terfenadine , astemizole , cisapride , midazolam , triazolam , pimozide , bepridil , alkaloid ergot , voriconazole , mix St. John 's Wort . 7 . Patients treat antivitamin K. Treatment low molecular weight heparin allow . 8 . Known efavirenz hypersensitivity excipients . 9 . Severe renal impairment . 10 . Severe hepatic impairment . 11 . Yellow fever vaccine ( yellow fever ) . 12 . Pregnant lactating . 13 . Presence toxicity &gt; 1 accord criterion CTCAE V4.0 , due prior cancer therapy . 14 . Recurrent diarrhea interfere drug absorption capacity . 15 . Patient include another biomedical research drug within 30 day inclusion . 16 . Patient previously participate study . 17 . Patient , reason psychological , psychiatric , social , family geographical could treat monitor regularly criterion study , patient deprive liberty tutorship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Solid tumor ( pancreas )</keyword>
</DOC>